Brittany Bruggeman, MD, emphasizes that many patients with type 1 diabetes are unaware of the availability of advanced technologies like CGMs and automated insulin delivery systems.
Brittany Bruggeman, MD, pediatric endocrinologist at the University of Florida and type 1 diabetes physician scientist, joined Contemporary Pediatrics to discuss the latest advances in technology for type 1 diabetes care. According to Bruggeman, “there are so many new aspects of technology that we now use routinely in type 1 diabetes,” highlighting the significant role of continuous glucose monitors (CGMs) and automated insulin delivery systems.
Bruggeman emphasized the convenience and effectiveness of CGMs, which allow patients to monitor blood glucose levels without frequent finger sticks. “People can rely on continuous glucose monitors for care and not have to do a finger stick, except for in very special circumstances," Bruggeman noted, adding that this gives both endocrinologists and patients peace of mind with round-the-clock monitoring.
Another important advancement discussed was automated insulin delivery systems, where insulin pumps and CGMs work together to automatically adjust insulin levels based on real-time blood glucose data. These systems, Bruggeman explained, are crucial for patients on insulin, yet many are unaware of their availability. She stressed the importance of ensuring all patients with diabetes have access to these technologies, stating, “Something important that every patient with diabetes on insulin needs to know is that these systems are available to them."
Bruggeman also pointed out the troubling health care disparities in the adoption of these technologies. Patients from lower socioeconomic backgrounds and minority groups are significantly less likely to use CGMs and automated insulin delivery systems.
“Unfortunately, half the rate of use of these technologies” exists among underserved populations, compared to non-Hispanic, White, more affluent patients. However, Bruggeman emphasized that “even with lower health literacy or lower socioeconomic status, people really can understand these new technologies.” She concluded that the design of these devices has become more intuitive, making them accessible to a broader population. As Bruggeman put it, “If you can use a phone, you generally can use most of these new technologies.”
FDA issues second CRL for dasiglucagon to treat hypoglycemia in congenital hyperinsulinism
Published: October 8th 2024 | Updated: October 8th 2024This decision marks the second time the FDA has issued a complete response letter (CRL) for dasiglucagon to treat hypoglycemia in patients 7 days and up with congenital hyperinsulinism.